Avid Bioservices Inc (CDMO)

[biopharm]

Results of the analysis demonstrated that the bavituximab plus docetaxel group did not show a sufficient improvement in overall survival as compared to the docetaxel group to warrant continuation of the study. The interim analysis showed that the bavituximab combination group is performing as expected according to the original trial assumptions in terms of overall survival, while the docetaxel group is dramatically outperforming overall survival expectations based on the original trial assumptions and as compared to recently published studies.

CJ, I wonder why all are not thinking straight and if all just take a big step back and look at the wording that you pointed out that many are missing...

1) This means that Bavi+Docetaxel shows an improvement over the Docetaxel+Placebo.... but not a "SUFFICIENT" improvement...

now combine that with

2) while the docetaxel group is dramatically outperforming overall survival expectations based on the original trial assumptions and as compared to recently published studies

now combine that with..

The long tail that begins about this time will not be officially recorded by the FDA....so that means that any Big Pharma running combo trials are SAVED by this trial ending now

Politics and politics and money... I hope Peregrine does a better job to convince those that can't see all this too easily